Pseudomonas exotoxin--immunotoxins

Cancer Treat Res. 1988:37:161-73. doi: 10.1007/978-1-4613-1083-9_11.

Abstract

Monoclonal antibodies can be coupled with PE to make very potent ITs. Two of these ITs (PE-HB21 and OVB-3-PE) have been shown to have antitumor activity in a nude mouse model of ovarian cancer. PE ITs are at least 10-fold more active than the corresponding RTA IT. Deletion analysis of the structural gene of PE has helped assign specific functions to different portions of the molecule. Current efforts are focused on making ITs with recombinant PE.

Publication types

  • Comparative Study
  • Review

MeSH terms

  • ADP Ribose Transferases*
  • Animals
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Neoplasm / administration & dosage
  • Bacterial Toxins*
  • Cross-Linking Reagents
  • Drug Screening Assays, Antitumor
  • Epidermal Growth Factor
  • Exotoxins* / genetics
  • Exotoxins* / metabolism
  • Exotoxins* / pharmacology
  • Exotoxins* / therapeutic use
  • Female
  • Genes, Bacterial
  • Humans
  • Immunotoxins* / therapeutic use
  • Mice
  • Mice, Nude
  • Ovarian Neoplasms / drug therapy
  • Peptide Elongation Factor 2
  • Peptide Elongation Factors / antagonists & inhibitors
  • Protein Engineering
  • Pseudomonas aeruginosa / genetics
  • Pseudomonas aeruginosa Exotoxin A
  • Ricin / pharmacology
  • Transferrin
  • Virulence Factors*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Neoplasm
  • Bacterial Toxins
  • Cross-Linking Reagents
  • Exotoxins
  • Immunotoxins
  • Peptide Elongation Factor 2
  • Peptide Elongation Factors
  • Transferrin
  • Virulence Factors
  • Epidermal Growth Factor
  • Ricin
  • ADP Ribose Transferases